Northwestern University scientists have developed a new bioactive material that successfully regenerated high-quality cartilage in the knee joints of a large-animal model.

Although it looks like a rubbery goo, the material is actually a complex network of molecular components, which work together to mimic cartilage's natural environment in the body.

Fewer side effects, improved chances of healing: the goal of precision medicine is to provide patients with the most individualized treatment possible. This requires a precise understanding of what is happening at the cellular level. For the first time, researchers at the Technical University of Munich (TUM) have now succeeded in mapping the interactions of 144 active substances with around 8,000 proteins. The results could help to identify previously unknown potential benefits of existing drugs.

In a hopeful sign for demand for more safe, effective antibiotics for humans, researchers at The University of Texas at Austin have leveraged artificial intelligence (AI) to develop a new drug that already is showing promise in animal trials.

Publishing their results in Nature Biomedical Engineering, the scientists describe using a large language model - an AI tool like the one that powers ChatGPT - to engineer a version of a bacteria-killing drug that was previously toxic in humans, so that it would be safe to use.

A new study from the University of Michigan Health Rogel Cancer Center finds that giving a fatty acid inhibitor alongside chemotherapy could improve the treatment efficacy for patients with brain metastases from triple negative breast cancer. The findings appear in npj Breast Cancer.

Previous work has shown that the brain microenvironment has very limited lipids available for cancer cells, making it critical for cancer cells to generate their own lipids to survive.

A team of researchers at the University of Michigan Health Rogel Cancer Center has designed a molecule that impairs signaling mediated by two key drivers of cancer therapy resistance. The design and preclinical evaluation of the inhibitor, MTX-531 was published in Nature Cancer.

Researchers, led by Judith Sebolt-Leopold, Ph.D., discovered MTX-531, a kinase inhibitor with the ability to selectively block both epidermal growth factor receptor (EGFR) and phosphatidylinositol 3-OH kinase (PI3K).

Researchers from Kyushu University have identified a potential therapeutic target for the treatment of advanced multiple sclerosis (MS), a potentially disabling condition associated with the central nervous system. In their latest study, conducted using an experimental mouse model of MS, they explored the role of connexin 43 (Cx43), a protein involved in cellular communication and cardiac function, and examined whether targeting this protein with specific blockers could improve MS symptoms.

A recent study from China has reported that Cordyceps sinensis (CS), a traditional Chinese medicinal fungus, can ameliorate idiopathic pulmonary fibrosis (IPF) in mice by inhibiting mitochondrion-mediated oxidative stress. The research, conducted by a team led by Huan Tang and Jigang Wang from the Institute of Chinese Materia Medica at the China Academy of Chinese Medical Sciences, was published in Wiley's MedComm-Future Medicine.